Simon Yau
Pulmonary Disease · Houston, TXNPI 1932494374
Payments from drug & device makers
Across 379 payments — averaging $96.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$24K
- Intuitive Surgical$5K
- Insmed, Inc.$932
- Johnson & Johnson$879
- Boehringer Ingelheim$673
- Actelion Pharmaceuticals US, Inc.$579
- plus $5K from 32 others
Across 1 payment — averaging $165.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Transmedics, Inc.$165
What the payments were for
- Consulting fees$2001%
- Speaking & faculty fees$21,59359%
- Travel & lodging$2,3877%
- Food & beverage$9,23425%
- Education$3,0698%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 67 | $24,171 |
| Intuitive Surgical | 8 | $4,611 |
| Insmed, Inc. | 47 | $932 |
| Johnson & Johnson(2 entities) | 6 | $879 |
| Boehringer Ingelheim | 29 | $673 |
| Actelion Pharmaceuticals US, Inc. | 23 | $579 |
| Shionogi Inc | 22 | $528 |
| Grifols USA, LLC | 19 | $468 |
| United Therapeutics Corporation | 21 | $387 |
| Baxter Healthcare | 16 | $366 |
| GSK | 17 | $352 |
| AbbVie(2 entities) | 15 | $247 |
| Mylan Specialty L.p. | 8 | $243 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $237 |
| Bayer | 3 | $234 |
| Regeneron Healthcare Solutions, Inc. | 8 | $232 |
| ANI Pharmaceuticals, Inc. | 7 | $183 |
| Pfizer | 9 | $173 |
| Sanofi-aventis U.S. LLC | 2 | $114 |
| Viatris Specialty LLC | 3 | $91 |
| Electromed, Inc. | 6 | $82 |
| Merck | 4 | $82 |
| Sanofi | 3 | $77 |
| Advanced Respiratory, Inc | 3 | $72 |
| Sandoz | 3 | $60 |
| Pharming Healthcare, Inc. | 3 | $56 |
| BD | 1 | $52 |
| Tactile Systems Technology Inc | 2 | $47 |
| Inogen, Inc. | 2 | $45 |
| AstraZeneca | 3 | $43 |
| Abbott | 1 | $35 |
| Pulmonx Corporation | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Alcresta Therapeutics, Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Caris MPI, Inc. | 1 | $17 |
| Medtronic | 1 | $14 |
| Resmed Corp | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CRESEMBA$22,804
- ION$3,000
- Da Vinci Surgical System$870
- Monarch Platform$840
- DA VINCI SP$720
- Adempas$200
How this compares
$36,483 in reported general payments places this provider in the 85th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 51 | $335,197 |
| PrevymisLetermovir | 45 | $328,688 |
| OfevNintedanib Esylate | 20 | $260,491 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 15 | $225,157 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 11 | $157,229 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 23 | $143,307 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 11 | $100,244 |
| CresembaIsavuconazonium Sulfate | 15 | $99,992 |
| EliquisApixaban | 88 | $82,467 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 27 | $74,406 |
| Atovaquone | 73 | $55,374 |
| Posaconazole | 43 | $38,651 |
| Valganciclovir Hcl | 179 | $30,927 |
| Voriconazole | 53 | $27,986 |
| Tacrolimus | 199 | $24,499 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $468 | $335,19751 claims |
| MerckPrevymis | $82 | $328,68845 claims |
| Boehringer IngelheimOfev | $673 | $260,49120 claims |
| Insmed, Inc.Arikayce | $932 | $225,15715 claims |
| PfizerPanzyga, Eliquis | $173 | $182,71199 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $237 | $157,22911 claims |
| Astellas Pharma US IncCresemba | $24,171 | $99,99215 claims |
| GSKTrelegy Ellipta | $352 | $10,41617 claims |
| SandozEnoxaparin Sodium | $60 | $9,11339 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Houston
- Ivan RosasHouston$13.8M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Zeenat SafdarHouston$1.7M
- Howard HuangHouston$1.3M
- Dileep PuppalaHouston$1.1M
- Sandeep GuptaHouston$1.1M
- Joseph VaronHouston$1.1M
- Bela PatelHouston$974K
- Roberto CasalHouston$865K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.